Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease.
Johanna LehtomäkiAnne NikkonenLaura Merras-SalmioPauliina HiltunenKaija-Leena KolhoPublished in: Scandinavian journal of gastroenterology (2021)
Higher trough levels in the first 3 months of adalimumab treatment are associated with lower rates of discontinuation due to loss of response during the first year.